The ITSN1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, featuring targeted disruption of the ITSN1 gene. This polyclonal mixture encompasses diverse genetic edits introduced by non-homologous end joining, providing a practical loss-of-function model for studying ITSN1 biology without clonal isolation. The product offers a versatile platform to examine the roles of intersectin-1 in endocytic trafficking and signal transduction within cancerous epithelial contexts.
A-549 cells were originally established from human lung adenocarcinoma tissue and exhibit typical epithelial morphology. As a widely used model in cancer research, these cells retain key characteristics of lung adenocarcinoma, including oncogenic signaling dependencies and responsiveness to therapeutic agents. Their robust growth and well-characterized signaling networks make A-549 an ideal host for generating knockout derivatives to dissect molecular mechanisms underlying tumor biology, particularly those related to membrane trafficking and cell migration.
ITSN1 encodes intersectin-1, a scaffold protein coordinating clathrin-mediated endocytosis with actin remodeling. Through its Eps15 homology and SH3 domains, ITSN1 binds endocytic proteins including Eps15, epsin, and dynamin, facilitating vesicle formation. Its DH-PH domain activates Cdc42, which stimulates N-WASP and the Arp2/3 complex to polymerize actin. This links membrane invagination to cytoskeletal reorganization. ITSN1 is engaged by EGF, receptor tyrosine kinases, and Src kinases; downstream, it connects to Grb2, SOS, and Ras, integrating endocytosis with MAPK signaling.
In A-549 adenocarcinoma cells, ITSN1 knockout allows dissection of how receptor trafficking and actin dynamics influence oncogenic phenotypes. Loss of ITSN1 alters EGFR internalization and degradation, modulates Cdc42-dependent actin remodeling, and impairs cell migration. This model is relevant for studying lung cancer progression, where dysregulated endocytosis and cytoskeletal rearrangement are hallmarks. Researchers can exploit this knockout to identify vulnerabilities in trafficking-dependent signaling networks.
Typical applications of the ITSN1 Knockout A-549 Polyclonal Cells include western blotting to confirm loss of intersectin-1 expression, immunoprecipitation to assess disrupted protein complexes, immunofluorescence to visualize changes in endocytic compartments, and functional assays such as transferrin uptake and EGFR degradation to quantify endocytic efficiency. Cell migration assays can further elucidate the role of ITSN1 in motility. These cells are well suited for drug response studies targeting endocytosis or signaling pathways. For further information, including lot-specific validation data or ordering details, please contact Ascent Research.
